Search

Search Constraints

You searched for: Author/Creator Prats, Jayne

Search Results

1. Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database. Issue 3 (22nd May 2015)

2. Bivalirudin Is Associated With Improved In-Hospital Outcomes Compared With Heparin in Percutaneous Vascular Interventions: Observational, Propensity-Matched Analysis From the Premier Hospital Database. (January 2016)

3. Cangrelor compared with clopidogrel in patients with prior myocardial infarction – Insights from the CHAMPION trials. (1st January 2018)

4. Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX. (August 2017)

5. Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention: Results From CHAMPION PHOENIX. (July 2019)

6. Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. (1st March 2019)

7. Comparison of Bivalirudin Versus Heparin(s) During Percutaneous Coronary Interventions in Patients Receiving Prasugrel: A Propensity‐Matched Study. Issue 1 (1st October 2013)

8. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Issue 10 (6th September 2016)

9. Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment–Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials. (May 2016)

10. Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. (24th February 2022)